Maudsley精神科处方指南(第12版)(英文版)

  • 作者 [英]大卫·泰勒(David Taylor)
  • 出版社 后浪丨科学技术文献出版社
  • 出版时间 2019-4
  • 定价 188.00元
  • 装帧 平装
  • 开本 1/16
  • 页数 760
  • ISBN 9787518952205

Maudsley精神科处方指南(第12版)(英文版)

The Maudsley Prescribing Guidelines

in Psychiatry,12th Edition

后浪出版公司

权威精神科处方指南

     

 

编辑推荐

一本为精神疾病患者开具精神科处方药物的参考书。本书被广泛使用,涵盖专业人士需了解的各种相关信息。包括如何开具处方、需要注意的不良反应、如何有效增强药效或更换药物,例如抗精神病药、抗抑郁药和抗焦虑药。初级专业人士通过阅读本书将获得精神疾病用药的基础理论、安全性和疗效方面的重要信息。经验丰富的临床医生将会从本书在他们可能不会经常遇到的更复杂的问题上找到很好的指导。

媒体推荐

“好书,执业精神科医师的‘必备圣典’……不仅夯实医生的精神疾病用药理论基础知识。更重要的是,患者必将受益。” ——人类精神药物学(Human Psychopharmacology)

 “对于直接参与精神疾病治疗的任何药剂师而言,无论其工作于基层医疗机构,还是高级医疗机构,我认为这本书都是必读的。”——药物杂志(The Pharmaceutical Journal)

 “这本综合指南……将帮助护士在与患者及其家属讨论药物时,在专业团队内探讨治疗方案时,以及与专业人士沟通时,保持自信、敏锐、博学。”——护理标准(Nursing Standard)

著者简介

[英] 大卫•泰勒(David Taylor

伦敦国王学院药理学教授,南伦敦和莫斯利国民保健基金会信托基金药理和病理学主任。

内容简介

第12版基于过往数据回顾和近期临床实践,提供了简单但详细的精神疾病和相关精神药理学的综述。主要介绍血浆药物水平监测、精神分裂症、双向情感障碍、抑郁症、焦虑症、儿童和青少年用药、药物滥用,以及特殊患者群体用药。每部分都有完整的参考文献,以便在需要时可以快速查询证据库。本书还介绍了尚未得到共识的药物治疗,以及药物与乙醇、烟碱和咖啡因的相互作用等方面的内容。

 

目  录

Preface

Acknowledgements

Notes on using The Maudsley Prescribing Guidelines

List of abbreviations

Chapter 1 Plasma level monitoring of psychotropic drugs

Interpreting sample results

Acting on clozapine plasma concentration results

Interpreting post-mortem blood concentrations

Chapter 2 Schizophrenia

        ANTIPSYCHOTIC DRUGS

General introduction

General principles of prescribing

Minimum effective doses

Quick reference for licensed maximum doses

Equivalent doses

Highdose antipsychotics: prescribing and monitoring

Antipsychotic prophylaxis

Combined antipsychotics

Negative symptoms

Monitoring

Relative adverse effects – a rough guide

Treatment algorithms for schizophrenia

Firstgeneration antipsychoticsplace in therapy

Omega3 fatty acid (fish oils) in schizophrenia

New and developing drugs to treat schizophrenia

NICE guidelines for the treatment of schizophrenia

Antipsychotic response – to increase the dose, to switch,to add or just wait – what is the right move?

Antipsychotic longacting injections

Depot antipsychotics – pharmacokinetics

Management of patients on longterm depots

Aripiprazole LAI

Olanzapine LAI

Paliperidone palmitate LAI

Risperidone LAI

ANTIPSYCHOT ICS – ADVERS E EFFECTS

Extrapyramidal sideeffects

Akathisia

Weight gain

Treatment of druginduced weight gain

Tardive dyskinesia

Neuroleptic malignant syndrome

Catatonia

QT prolongation

Dyslipidaemia

Diabetes and impaired glucose tolerance

Hypertension

Hyponatraemia

Hyperprolactinaemia

Sexual dysfunction

Pneumonia

Switching antipsychotics

REFRACTORY SCHIZOPHRENIA AND CLOZAPINE

Clozapine – dosing regimen

Optimising clozapine treatment

Alternatives to clozapine

Restarting clozapine after a break in treatment

Initiation of clozapine for communitybased patients

CLOZAPINE – ADVERS E EFFECTS

Common adverse effects

Clozapine: uncommon or unusual adverse effects

Clozapine: serious haematological and cardiovascular adverse effects

Clozapineinduced hypersalivation

Clozapineinduced gastrointestinal hypomotility (CIGH)

Clozapine, neutropenia and lithium

Clozapine and chemotherapy

Chapter 3 Bipolar affective disorder

        Lithium

Valproate

Carbamazepine

Antipsychotics in bipolar disorder

Treatment of acute mania or hypomania

Bipolar depression

Rapidcycling bipolar affective disorder

Prophylaxis in bipolar affective disorder

Physical monitoring for people with bipolar affective disorder

Chapter 4 Depression and anxiety

        Introduction

Basic principles of prescribing in depression

Official guidance on the treatment of depression

Antidepressants: general overview

St John’s wort

Recognised minimum effective doses of antidepressants

Drug treatment of depression

Treatment of refractory depression

Psychotic depression

Electroconvulsive therapy and psychotropic drugs

Psychostimulants in depression

Poststroke depression

Treatment of depression in the elderly

Antidepressant discontinuation symptoms

Antidepressant prophylaxis

Antidepressants: alternative routes of administration

Antidepressants: swapping and stopping

Drug interactions with antidepressants

Cardiac effects of antidepressants

Antidepressantinduced arrhythmia

Antidepressantinduced hyponatraemia

Antidepressants and hyperprolactinaemia

Antidepressants and diabetes mellitus

Antidepressants and sexual dysfunction

SSRIs and bleeding

Antidepressants: relative adverse effects – a rough guide

Anxiety spectrum disorders

Benzodiazepines in the treatment of psychiatric disorders

Benzodiazepines: dependence and detoxification

Benzodiazepines and disinhibition

Chapter 5 Children and adolescents

Principles of prescribing practice in childhood and adolescence

Depression in children and adolescents

Bipolar illness in children and adolescents

Psychosis in children and adolescents

Anxiety disorders in children and adolescents

Obsessive compulsive disorder in children and adolescents

Post-traumatic stress disorder in children and adolescents

Attention deficit hyperactivity disorder

Autism spectrum disorders

Tics and Tourette’s syndrome

Melatonin in the treatment of insomnia in children and adolescents

Rapid tranquillisation in children and adolescents

Doses of commonly used psychotropic drugs in children and adolescents

Chapter 6 Substance misuse

Introduction

Alcohol dependence

Opioid misuse and dependence

Nicotine and smoking cessation

Pharmacological treatment of dependence on stimulants

Benzodiazepine misuse

GBL and GHB dependence

Drugs of misuse: a summary

Interactions between ‘street drugs’ and prescribed psychotropic drugs

Chapter 7 Use of psychotropic drugs in special patient groups

The elderly

Dementia

Safer prescribing of physical health medicines in dementia

Management of non-cognitive symptoms of dementia

Parkinson’s disease

Multiple sclerosis

Huntington’s disease

Pregnancy

Breastfeeding

Renal impairment

Hepatic impairment

HIV infection

Eating disorders

Acutely disturbed or violent behaviour

Borderline personality disorder

Learning disabilities

Delirium

Epilepsy

Surgery

Velo-cardio-facial syndrome

Cytochrome (CYP) function

Psychiatric side-effects of non-psychotropic drugs

Atrial fibrillation

Chapter 8 Miscellaneous conditions and substances

Psychotropic drugs in overdose

Biochemical and haematological effects of psychotropics

Prescribing drugs outside their licensed indications(‘off-label’ prescribing)

Observations on the placebo effect in mental illness

Drug interactions with alcohol

Nicotine

Smoking and psychotropic drugs

Caffeine

Complementary therapies

Enhancing medication adherence

Driving and psychotropic medicines

Covert administration of medicines within food and drink

Index

 

前  言 

This 12th edition of The Maudsley Prescribing Guidelines in Psychiatry marks its 20th year in continuous production. Readers who have owned or used previous editions will find this edition no different in style from previous incarnations. This is deliberate – the feedback we receive suggests the organisation and structure are well liked. Each section of The Guidelines is a densely referenced but succinct review of the literature, set alongside some fairly broad recommendations for practice. Each of these sections has been updated and revised, and some new ones added (for example, interpreting clozapine plasma levels, postmortem plasma levels, summary of depot pharmacokinetics). Much of the guidance provided in this edition has changed as a result of more recent research; some of it to a small extent, some of it to an extent amounting to a reversal of prior guidance (for example, on the use of fish oils in psychosis). These changes reflect the very nature of the scientific method – that hypotheses come and go as evidence mounts or is countered.

This edition of The Guidelines has a particularly international flavour. This is because the 11th edition sold more copies outside the UK than in it, and because there are, we think, at least ten translations of The Guidelines in existence. Although The Guidelines are still essentially our local guide to prescribing, we have made a special effort to widen, geographically speaking, its utility. This is most noticeable in the inclusion of drugs not licensed in the UK (e.g. ziprasidone, iloperidone, desvenlafaxine), but widely used in other countries. Readers should, therefore, not assume that every drug mentioned in The Guidelines is available in their own country. The reader should also be aware that no guideline could take account of every psychotropic drug used around the world, so omissions are inevitable.

1.       As with previous editions, very special thanks are due to Maria O’Hagan who manages the writing and structuring of The Guidelines; an increasingly complex process given the size, complexity and heavily referenced nature of the current edition. Thanks are also due to the many expert contributors to The Guidelines who are listed overleaf, and to Adam Gilbert, our editor at Wiley.

David Taylor

出版后记

服务热线: 133-6631-2326 188-1142-1266

服务信箱: reader@hinabook.com

 

 

后浪出版公司

2019年6月


电话咨询
邮件咨询